ABMD - Earnings call transcript Q2 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by and welcome to the Abiomed’s Second Quarter 2021 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference maybe recorded. I would now like to hand the conference over to your speaker today, Mr. Todd Trapp. Sir, you may begin.

Todd Trapp

to quarter welcome call. XXXX and morning Abiomed’s fiscal second earnings Good President Officer. is and with am Chairman, President Trapp, Mike Chief Financial Abiomed’s This Vice I Chief Todd Officer and Minogue, and Executive here The format will call for follows. be as today’s

second results, to First, financial we operational highlights review were will After your that, outlined in open business and Mike quarter and call I questions. then will will release. the discuss which our today’s press

and call to any with involves differ not me Officer, identified Before statements. Abiomed’s the includes and we today’s We President do would to of everyone that XX-Q forward-looking statements obligation results turn like materially SEC. company forward-looking to remind Chairman, in are With a Chief earnings variety begin, recent and filed risks our release factors our investors the cautions may that, in to undertake press future. forward-looking and Actual update The Executive that statements. I our over due uncertainties let Minogue. not call any XX-K Mike most guaranteed and

Mike Minogue

and good everyone. Thanks, Todd morning,

Over patients, and by the the and have we COVID-XX artery customers coronary disease. employees to presented past months, challenges X our navigated

adapt and been ability put first as patients Our strength. an organization to has execute and our

first We in hemodynamic lives everyday. for support. procedures operating innovation and the revolutionize and to save have investing from standard created of recover leadership and of care customers I patient’s new while and the to significantly commitment Abiomed our X.X hearts proud the clinical employees research am

in which moved to phase sequential our on were and COVID-XX growth to cases, QX restrictions year-over-year the the address designated of growth, hospitals handle essential reflecting on access preparing the positioned we better return quarter a X.X to and and three elective evolving summer our headquarters’ and was For and We geographies focused hospitals Abiomed to the red, environment. acceleration phase during phase on green occurred to we limitations resurgence of QX, with patients. In meetings fiscal approach with yellow broad yellow, to COVID-XX operations. travel ‘XX, the limited red the procedures.

However, QX. in two challenging elements remain

emergent First, seeking patient urgent and anxiety delays treatment care. for in caused

impacted Second, for in coronavirus. home steady patient and longer, delays has in cardiogenic cardiovascular This factors availability the and patient phenomenon high-risk for further treatment keep been ICU These patients simultaneously risk shock. referrals, causing suppress without referral rates. network shock hospital reported increase patients cardiogenic PCI

COVID in and be surgery and open at environment, in less the populations However, PCI preferential hospital patient the heart high-risk tend failure staging sicker. heart this CABG to are called risk higher

our Abiomed QX, As recovery up have sequentially phase, pockets a delivered Europe and across result, growth U.S., year-over-year. up and QX over of X% in and in the XX% $XXX sustainable we Japan. million QX yellow revenue, In

revenue increased innovation increased to quarter, with the focused and strong do plans. at operationally remain and goals volatility upswing growth patient led delivered and on that the we for company. month, cardiogenic our continuing Europe XX% shock. XX% we recovery ‘XX expect in quarter the levels linear PCI in we but the Outside During tactical this and utilization U.S., in positive operating invest in QX, of research Despite and recovery given record believe resurgence. saw XX% within year-over-year Japan. disciplined while as margin, will in fiscal the continue, crisis both We and by high-risk trend perfectly COVID the each essential a increased not sequentially procedures We

with patents U.S. of the and Overall, and goals portfolios we XXX proud regulatory, U.S. patents report revenue to double-digits sheet in balance milestones. our and engineering of $XXX expand increased in the patent outside achieved and grew political revenue lead remains our zero our and to QX phase pending. debt and med-tech, with Our Impella we cash one am yellow robust million sequentially, continue with strongest that while in I the stabilized advancing XXX

For planned to data; second, technology Impella on phase; and green will our first, our new third, transition call, three new the on updates: the I today’s progress clinical provide milestones.

we QX So yellow page first, goals. operationally, achieved our

online, weekly supported manufacturing in calls trained also to X,XXX to ramped with We cases. virtual the and training backup Massachusetts and Germany and physicians and continue protected production expand pci.com and in live full Aachen, Danvers, Impella quarter we PCI over education leveraging with

for presented pump means Abiomed first and Danvers from innovation, a study maximize offense Connect adoption. company’s screening in these also emergency which in routinely to is COVID-XX. and COVID Abiomed improve FDA PROTECT with in II to FDA and in of coronavirus. demonstrates no of second EF To prospective PROTECT Restore study, in out the preparing as and bleeding prospective to patients rates and of green improvement of study. of in transition the multiple post-approval supported compared for allows and the utilizing even Impella lower Aachen. network compared complications, third studies with achieve protected outcomes PROTECT our note, in cardiogenic authorizations result PCI the to of to with execution Impella quality Impella validated of for transition facilities use treatment. and timelines now with technique. benefit are fraction debatable. COVID days X.X% the The update, referral and more phase endpoints life Transitioning stroke fraction X.X% or at to X studies vascular and at rate our are TPT PCI. patient most was for presented the clinical training, end the look is and X%, Impella are PCI weeks And in minimize and X.X a demonstrates in to This Class clinical defense, of in pump than treatment highlighted we playing longer at versus PCI as ECPELLA ejection grow post-cardiotomy the TCT the stroke green adapt XX we anxiety my protected data employees testing by balloon Impella with We statistically despite manufacturing and the protocols clear including resurgence we improvement those robust our history. to including and patient newest harmful higher the the now three in and invest XX Impella the presentations This The was and X the stage ago, Internally, shock main data Impella treat to abstracts, the enabled record than our protected III PROTECT are protocols failure, being a and quarter heart United objectives intra-aortic our II III on number time data us balloon the respectively shock. hospital intra-aortic cardiogenic X.X States ejection

Impella hosted found link we the originating heart Medical website. with to As Q&A with can FDA our on Impella and authorizations failure. for Impella for Recap has this over our of right emergency RP XX XXX by effective completed webcast protective a and cardiogenic X received and Impella reminder, the is TCT use Chief exclusively week validating PCI for COVID-related and be today. clinical in or studies, history also XXXX led FDA as studies to years pump heart ongoing, ECPELLA the a continuing studied post-marketed in FDA safe call X of investor a shock Impella studies completed complications. and Officer last publications, and most

guideline Class recommendations X best to and practice we We protocols with IV publish will PROTECT DTU, pursue as study RECOVER continue IV and studies. STEMI

fiscal or study year DTU PROTECT and the our enrolling this ‘XX. of IV fiscal goal We first for plan of STEMI treated are at our to with currently QX the study our initiate patient end year

Impella to with administer clot. allow After was is the Andrea RP her discharged when for XX-year-old where would clot. her fraction later was home I the explanted. highlighting X and Gardens to followed a for son-in-law Patel her grateful grandson. and pandemic, retired Dr. by to failure. the she our convulsions. story symptoms Her Andrea grandson the the treat dissolve with other heart share the a of of was grateful days Fetter, weaned like pump right to to Despite Now, Beach her teacher, with percutaneously her heart and Nishant Andrea rest visiting dizziness by to symptoms. Andrea was diagnosed heart time and hold drug percutaneously normal benefit right life experiencing heart Palm the exclusive daughter ejection Impella she threatening Today, X-day-old especially to week patient ventricle right He RP is the of Medical began ventricle. recent Center day ambulance and family rushed Impella and quality in Florida, next inserted returned her concerning failure, RP a support,

Impella continue on now surgical our Moving to year-over-year with smaller, implant and make pump our management, and with of connected. axillary artery the sites, to we X.X for designed identification heart on update products to support U.S. right flow revenue the weaning algorithms than The SmartAssist increase at smart of This via smarter X.X full to and pumps. XX% coring driving XXX easier a ventricle third avoid failure. the heart forward left in for sternotomy is pipeline, smaller and product is the provide heart hemodynamic more

designed record testing with continue surgeons heart for the positive on and the blood needs. also to is compatibility receive for This clinical We positive feedback device beds. on the game-changing most answers data

Our doubling to live of exclusive is sites XXX Impella accounts more U.S. the than last Connect quarter. number now at compared capability

of the now half our Connect. nearly with U.S. in monitored are Impella Additionally, patients cloud

sites with only permission hospital We on the Impella the console, have already the account. hardware Connect XXX additional to an WiFi activate requiring

XXX(k) a X.X for for end and Impella of quarter on XR the remain the track release market QX. Sheath submitted we for Lastly, last the with limited by approval

key our System Abiomed’s will controlled announced our ahead the are hospitals in of five On QX. regulatory Breethe initiate October delivering on OXY-X first XXX(k) launch at XX, of We schedule clearance milestones. we and

add ECMO unloading We are of end clinical excited and to ECPELLA. combined very oxygenation to include organ with therapy capability

with cardiac respiratory have at stands will October to first-in-human X-French the of is is with announced phase procedures in innovative performed second to with COVID-XX in present successfully early coronary smallest U.S. St. a to patients XX, everything, expandable artery the ECPELLA benefits FDA care. the half more We Cincinnati. Hospitals the study high-risk believe heart, X.X bedside seek power, when the successful access be light CP COVID heart at our better we PCI. full In crisis, patients alone. fear During two green ECP, are further them an patients online conclusion, in Hospital and yellow COVID-XX of in Impella we the true our resurgence home, On world’s and transitioning in and year. at studied allowing executed the and expand changer The swing population support two kidney of now with game are phase of series which closure patient failure Impella for and COVID-XX a Ascension high-risk and they hospital The causing XX/X. disease to the fiscal is prepared we and John and keeps cloud patients for during the Christ ECP, flow. patients were the include pump. for the of pump the therapy this some physicians Detroit in handle Abiomed feasibility lung

No this of our and unique competency. patients. goals focused has clinical oxygenation other growing for coronary artery Abiomed, remain for heart improving ‘XX platform Impella technology outcomes Our and organ encouraging muscle in or provides med-tech core At revenue. we innovation, company achieving steadfast vision disease, recovery innovative fiscal coronavirus, solutions ECMO shock on and

as We are their customers for over this COVID-XX journey. we and work recovering to company, dedication support on to hearts offense will and We hard Todd to thanking now the saving our end clinical lives. our emerge the with turn CFO. appreciate will I from by our will for and and uniquely call I Trapp, research their a of playing care. change shareholders positioned technology standard and continued stronger employees

Todd Trapp

million, $XXX prior Thanks, year. Mike In we sequentially X% of versus everyone. quarter, the XX% and increase of delivered and of an an increase good morning, revenue

geographies our we negatively revenue XX% a saw $XXX region, sequentially and gradual key While of sequentially XX% X% be reported the versus business our up the AMI increased high-risk respectively. COVID-XX million, to Sequentially, XX% impacted by and shock Versus utilization course increased and improvement patient grew prior year-over-year. PCI X%, PCI shock of the down was continues in quarter. flat while the U.S. declined patient year, cardiogenic high-risk pandemic, U.S. X%. in over utilization XX% year. cardiogenic and prior By

in and resurgence utilization saw key which we markets, impacted call, last California in that some of cases our COVID Florida, on in discussed we As month. our as across our such July Texas,

in these sites. we The saw August end a and in regions a the been September, and in X,XXX X.X sites and XXX and a patients market of XX Impella In XX% X.X placed some deliver U.S. versus year. X.X the in recovery see at did the full prior including sequential the the we quarter, portfolio, Impella Impella surgical Within U.S. X.X, release CP has reached with now left-sided sites versus to and overall the X.X in revenue XXX of is in The our increase of improvement the have as reported X.X quarter. up the sites, continues SmartAssist prior Impella LD the September.

see a quarter. QX In versus Impella Average revenue CP quarter. we CP to over to improvement the inventory Finally, with revenue with sites, XXX%, year. levels sales Impella was $XX RP and hospitals million, mix was the to last combined line and sequentially X.X the U.S., is versus XX U.S., approximately saw with and XX% increasing RP quarter, up site SmartAssist. slight X.X totaled sites XXX X% at up with In continue prior the per the the in the favorable as year-over-year. X.X we units rate last Outside SmartAssist reorder we transition XX% inventory Impella the Impella in up

Our by and sequentially XX% favorable European and versus exchange. revenue driven in in prior Germany, increased Switzerland year foreign recovery Italy XX%

and single-digits foreign quarter. XX% The performance year. year-over-year versus up In was reorders. utilization XX% which offset million up favorable and higher sales. driven driven was Germany, sequentially utilization, PCI $XX Specifically, patient console sequentially grew in XX% primarily year-over-year, by prior up Japan, cardiogenic and side patient German by up up in In mid XX% was utilization, revenue, Germany year-over-year. X% sequentially timing in we and and high-risk exchange up in delivered by QX, lower higher XX% both of patient the revenue was shock openings partially In

earnings we the XX site are our now sites Japan. call, openings communicated We in discussed versus on last sites quarter XXX up year. in the lower quarter As prior in and opened in

the Impella financial costs quarter year. key margin was to Moving metrics, rollout. the gross by and XX% incremental to to in prior accelerate was mix compared year-over-year The variance in the Connect driven XX.X% sales

phase in objectives of the of One main second to despite expense quarter, In R&D was the invest prior our during $XX short-term yellow the an continue totaled innovation to year. headwinds. million, increase XX% versus

investments the We small focus the with to XR with pump ECP the continue on X.X the Sheath, X-French barrier SmartAssist. breaking in in Impella

trade while costs related investing IV, T&E QX in operating what improvement Abiomed mark-to-market believe income and share second million, In or our and and shows. long-term We to a education $XX remain We We X% and an are margin of was achieving Shockwave diluted on $XXX translating the are disciplined including $X.XX our or including quarter Class X% driven our cardiogenic $X.XX delivered expense by margins operating STEMI, income necessary discretionary of expenses high-risk lower benefiting quarter, from $XX rate. million versus primarily innovation, X.X, clinical lower was effective of net and XX.X%. year-over-year The to the in the down investment per COVID-impacted DTU, for tax clinical making for grew million, drive ‘XX. shock. data year. on like investments we online versus SG&A the GAAP growth. prior to studies managing are and training strong focused in activities, IV $XX in RECOVER on and goal and also the PCI recommendations STEMI with quarter million, also totaled PROTECT AMI X

another was Our tax year XX.X% in flow. the benefits operating cash this had year’s versus solid rate. rate to for prior million quarter generated we in XX.X% as excess tax $XX cash on QX due of higher We

cash with which and million no flexibility. and us Our $XXX security balance the quarter ended as continued sheet is of securities and marketable we provides robust debt,

and evolving impact of continue physicians. we of pandemic differently needs the across meet to With will patients the the adapt geographies, to

transparency quarter. that our expectations the in remains Similar give see improvement QX, in performance expect quarter. much is time, to on we unpredictable to our top a there to revenue do to our we during investors Although color line want provide third to this sequential throughout for

be of to position this factor current a manage prepared resources expect We under needed a being hospitals the be better in anticipate circumstances. and with to the to patients

begin $XXX $XXX QX of more risk to QX compared the increase time, to return we to revenue to sicker year. growth of an expect million be also patients to We flat system as the million, high X% range expect in in for volume At global last care. to representing this

So performance despite operational solid delivered the in financial the in summary, unpredictable and we quarter. environment,

focused standard phase, While of transitioning we executing Operator, formula of to the ‘XX and uncertainties while proven with bills please through a questions. care our the data progress fiscal continue of now time. line we navigate training remain the pandemic, and through green changing Impella the towards on open towards we for

Operator

[Operator question William from Kaczor Instructions] Blair. first our comes Margaret from And

open. Your line is

Margaret Kaczor

for the questions. taking Thanks

First, to on a your to wanted Mike bit here. on green and the being I comments, talk phase little the able go offensive about

can us us patients you of in then more get the the fears? up patient go what those had be means? on hospitals give to get is try talked to able and So, may coming something it more little around third that these referral or being about can fiscal and networks backlog a directly that that Is And and kind reinvigorate out sidelines of our quarter? some into them about address color that bit Abiomed or you give

Mike Minogue

for question. the Margaret, Thanks,

the teams and am the quarter year, the getting engineering me work, very clinical and well and about are doing the fiscal green most to as that as the Let in I future. the start important optimistic impressive saying by

So cover to it go what means they to green.

patients that So STEMI. the the because it are population has we the hospitals balloon transition time wait means to door longer, than is to Patients ever in at want ever treat more Because non patients before, this the green, sicker than been. to greater longer. is

So everything from factors at patient the urgent PCI, patients is risk highest hospital cases emergent have risk sicker cardiovascular we our have some and have perspective. Abiomed, patient risk. every we we have don’t high any higher patient, We the have any as a and of of a in elective

execute. So the that are to that part I are working which of mean, and with us adapt prepared. and the able we the doing societies way is starts means to And better need be we with much hospitals it being prepared. better

So we have from temperatures, in-house. more testing SpOX better airborne, it’s have to we COVID, know looking your knowledge around we and

and testing and we And better is XX have routinely some hour. and tests facility or testing within we are are antibodies And that an having our endure. We those those over starting where we can we a immunity with treatment for from we what of week what we some Aachen, of waiting in now hours control, plan But are for PCR, what XXX now antigen at are course, that to, within in there and vaccines. leads have know can influence the know having our everyone is it is us then already. we we know Danvers

we work working shows we and education helping to identifying road and up. directly those to just are are referral online, controlling the training protected and do. working that the we physician CAMP And things also the tend have we things like connecting around and so engineering, by needs We for with of things commercials we by And certain we are our of are with endorse to or influencing service helping with our then running investments with milestones, physicians. PCI by societies pattern the things the and a regulatory filling public combination to can is with where ICU seek PCI. influence the And champions heads

half the the the we are things So, year. of doing very about optimistic and those again, are second we are

Margaret Kaczor

I which guidance, third if can, then into quarter ask about of great. bit that. will Okay, stems a I And sort little the

as increase single-digits. are third guys You pretty go sequential sequential up mid – a into pretty nice we that assuming a quarter

thinking we as can did give of seem that prepared, and spoke just low the of those COVID are doesn’t gets guys. better getting Thanks, me think it range? range on you number kind to end that implies, kind about end, So, maybe not but if what a imply you some and below of what headwinds, you high incremental to necessarily above the you or potentially

Todd Trapp

Yes. Thanks, Margaret.

this Todd. is that take one. I So, will

prepared we to business. do from the remarks, So, to of expect as the gradual see continues sequential as my I recovery seasonality do QX improvement in our QX in mentioned we

the on the range depending would and within today, in guidance forecasting not we the growth quarter, the it impact have specific XX% basis. quarter we to within again, of low I of a So some the of assumes recovery really end are full the on see as X% resurgence say see sequential we that past. the in expecting the the hotspots seen to COVID

year-over-year So resurgence July, about grew quarter. and cases in made to saw recovery but Florida, in actually August we a in think strong September we

are and of call EF. sequential some that the would just So, highlighted we of of elective, to as know the tough they of but and hemodynamic it’s in And from from transparent are prepared lift but a trends patients handle Restore know to the Mike resurgence. our hospitals the will going we data end as are the are to again, TCT around bounce – that range, the to say, they see PROTECT clinical the gradual continue be to III need on are And the we timing the we improvement, sicker is robust recovery high support. the happen continue you again, now better back seeing. earlier call, I on

Margaret Kaczor

Todd. Thanks, Great.

Operator

question And Sandler. Piper O'Brien from Matthew our you. from Thank comes next

is open. line Your

Matthew O'Brien

think just probably are people morning. little softer in thought QX a on weakness bump you into guide, the what just Thanks. the we in on there lot the a I based like some still here. a interest know especially nice versus side follow-up would a QX I it’s than is U.S. a that RP, things. easier to high-risk level may X.X that think I on QX. little I about have little the PCI it’s said Good And bit would have bit sequential of bit on expecting and it But based imply just comp of

that you And Mike, be you do this done can why time, a as to you case? on just talk that that historically the trying predict? about to then would a either just are kind So, just approach different as or this little number variables conservative have similar bit long possible are is of be given all these difficult

Mike Minogue

the So, question. I the take for will This is Matt, Thanks Mike. question.

it’s say in have to quarter. we knowing for company. I the the are year our ever the had last was guidance the analysis history States where think on a given good companies fiscal back highest or To most for the month haven’t in October we patient that of look United guidance

coined then we in hospitals So, that is are California. We confident back a a it October what range shock on. but In have light for at of comp. And up, are hospitals knowing ICUs the to but September, also as itself, reason. that prepared, fill there it. And some as believe local somewhat, that numbers cases. sick. the and the we And the it to are Todd or easier are our guidance do knowing data. is if access goes to together is we the and But are a not better bit there Germany, mentioned, resurgent cases we a has patients from areas new COVID in have you seeing a benefiting are most that they a the way are we that be with are gets prudent meaning up therapy, exception anticipating is this are to they very think treat do working we there get little sick these sequentially expect tougher societies team it’s It’s quarter give from seeing the as these they up high-risk

does the our of numbers. many taking that the for not up, are global patients, care. account we U.S. And and backlog beds a the the to balancing And they ICU don’t but just some limit we die are unfortunately, of it numbers, treated unfortunately, they we so them in will are create will And permanent to if be fill that into have treat they will these the that if damage need not future. the or patients treated, some are ability restrict

but we we in able to where of full the situation best that QX, and to again So, green. prudent we year-over-year are confident to a be guidance to in as we do about we to to going the sequentially, to growing are are be here the are quarter summer try our this ultimate in continue grow to looking going transparency give into we what transition coming goal are did with at

Matthew O'Brien

say QX XX. timing is on track Okay, you then for of of fair enough. the that And on the side steep do things, great hear to that

can For you up these PCI this even XX we at don’t there that how in point. really is used of often launch into get limited anymore that kind frame the cases

sheet, and you. it’s ‘XX? going to QX, QX, be given product that into Thank could that So how of be that even fiscal XX impactful

Mike Minogue

of question we because used the have the Impella Now, less CP. is X.X

it population a patient at that However, out there’s are used probably there doesn’t more out all that there female. get

to in that the access only bailout closure, it a PROTECT worried X.X. see use our were at You willing studies physician patient next that individuals more be is for more remember, And was size population. might where That II group. smaller that about

in with lot a currently days. getting are those out and smaller of get cases, is back And out, meaning likely pump. stage CABG than are a doctors bring patients comfortable. in or in lot female more these balloon down XX something patients, COVID They some In we get is the and places a So that using they It CABG. not environment. we are to patients more going And are of they more to they many just and are those think again are high-risk does staging going get certainly either will and getting new, it less trying balloon pump. to

to in referred interventional cardiology. be to going are they So

our protected of We risk that also XX% user PCI. is relaxed expert single by know that PCI, around experience access high their for more

statistically are So we are adopters are trying a versus is us around we Intra-Aortic those in that II and of closure versus that the majority important. majority. are users, late access they have lower, numbers, show is you complications And single especially to access better Balloon the product that And we cases doing with seeing are continues really leverage is our now very data that III why grow. comfortable very what are the we PROTECT PROTECT to some early vascular early that know than the address And really numerically different Pump. levels the to

because proven of back and we So new doing from now the goal the and is in that really physicians XR the by is our a well. as some of in within going doing get that the minimize education holding fear program, and keeps that, again, and closure and then revascularization to multiple the is been complete including training PCI access are combination of out improvement to the That that think sheets studies of that there, of we in studies, EF quality enable life. you FDA data improvement the

Matthew O'Brien

Mike. Thanks helpful. Very

Operator

you. Thank

Guggenheim. Our from next Pasquale question Chris comes from

is line sir. Your open

Chris Pasquale

the more of Mike, expandable CP on sheath your up timing product what’s in mix? the on version, because obviously is current terms following just question, compatible the that meaningful

Mike Minogue

release the following up is end will to to And QX the the then are quarter, going or then said CP. have us XXX(k), and that continue on are we it, cycle, lead for that of so we we CP. limited about submit for QX talking on market and depending the to the What we follow

Chris Pasquale

the FY stop in ‘XX for of the release. first market sometime so Okay, about half thinking

Mike Minogue

Correct.

Chris Pasquale

Okay.

Mike Minogue

already note Motorhead, all have XX-French CP lot catheter of is the is to talk sophisticated users, one Impella, and a at the a the it, the mastered would some look doing for way same when has just through. we that and CABR the other about pump I of the though, Impella so things rest X-French. of cannula the Remember, centers they XX-French those

is because and expands So, our sheath unique that’s XR it why recoils.

with can you So close X-French. a

doing ones comfortable who that’s significantly a easier So, the even are TAVR. than

the the And best access looking III important, rates really is is event the again, bleeding, two last practice training, case at very looking the stroke, technique on single similar adverse the that know statistically balloon We and historically complications such are pump. than most you have is we seen what and also PROTECT you years, better over shows as II complications balloon rates outcomes around are the and the what in PROTECT of vascular at pump with popular.

Chris Pasquale

think help a me. I maybe for Mike, point, square Yes, good this that’s

the business, solved is we vascular complications this down, catalyst solving sort sheath have already easy by that’s better large bore a context, in that technology closure. gotten problem so or for at a been other Given of are expandable real evolution areas?

Mike Minogue

a the It’s of all above, It’s Chris. combination.

different have comfort size So, remember, levels. users and we different

are we are is giving education. we what solution doing regular with So, a starting

net give it those in one get what of what years And results actual and point of out a not the vascular the an odds to publication this does It for and are Here complications, you ratio. components. circulation for the you of thing just X see outcomes three last mean, gives in stroke. any bleeding

the are numbers, So, see to of because try to lower, but net you of investigation own are it. can out that when reasonable they in our a we single-digits, put doesn’t and buying because data, those and is X,XXX database pump pursue in will all to track a continue patients the that P have low value balloon single-digits patients, you you XX,XXX get X% even difference Impella it’s circulation

as reasonable high-risk we way going support best a that same today goal well the CABG life and where the do really from III of vein quality because the the for drive they gotten ultimate best believe around practices, are we ejection sternotomy. data continue remove the a without Restore that in are do single improvement event very get to a in proving is we So, to invasiveness fraction, the are the PCI, having can to rates physicians physicians, in if a you message EF we sow where to adverse we have has in going it PROTECT to of hemodynamic education. really We setting, you and to in those are patient’s the an of is complete and to as benefit revascularization able the the achieve overwhelming hearing being and the number is

opened us for time clinical exciting new far a education world And opportunity really most for the COVID up it’s as has data, the So, as training. us. and

know we cases. to they at have where they their plan because cases able we know we have to online are the of they users them live to shock. going who We education. Impella identification, know trained before password getting outcomes, and in. them can ever education more sole are PCI We log so where have are, protected in know we indications, to high-risk our do making Connect be they And do now than and with training But goal outcomes we cardiogenic both more training input with from weekly for online improve comfortable, and their and continue

centers. things masses care what logging large are So, to other from the trying for be the the cases to going questions whole are ago. and while year physicians things positive we is become This standard there many have of there did small watching you to And answering a COVID is negative network and with not now exist on of and to is very each train with that if world, a lot us. do

are so us And to it taken be we from without X get world we a have – Impella X to would where normal to to XX everything have training, think with COVID. going we in would able in Connect months we XX online years are to doing

Chris Pasquale

we the impact actually for this of last That’s Are past highlighted point up who over the on wouldn’t treating, in me gotten about have quantify some or you you you have year, can Thanks. months COVID of helpful. so. silver some otherwise through seeing utilization have patients the COVID-related gone meaningful to at one linings you picking you be Thanks. just maybe X approvals all? what that And your that

Mike Minogue

Chris. pieces I answer, to think there two are that

all sicker. First are of because is COVID, that majority they patients our the of

been Xx now rate. it’s rate. average STEMIs is door-to-balloon higher time an than So, a the non-STEMIs mortality have higher mortality have higher a

when that are is it there patients increasing get component to hospital. So, sicker they the although

is just getting we failure a around there education unloading for embolism that opportunity, we pulmonary get to lot COVID but For well people need think more itself, are still in as both right I incremental heart as and do ECPELLA general. some

continue are to going that those further we on to populations. publish on So – papers

Operator

you. Thank

Our next question comes from Raj Denhoy Jefferies. from

Your open. line is

Raj Denhoy

some Hi, could from Mike, feasibility device. start be broader? week, to describe thanks. quite Good when could past Maybe I what feedback you more and the news about positive a there you early like with looks that bit that a Maybe, of seemed to here early ECP study transition the on morning. this initial little and something

Mike Minogue

Sure.

do. co-inventor original the difficult The was Company, for while. Detroit in case. has and trying not first of very These for was it. I on been to in secure to to Impella been Officer, from back a Siess, I is able Technology Impella it our get closed Chief And a the So, works the pumps we ECP are day when I I ECP the bought had Impella. Thorsten

our would being utilize see back. to it one the it probably in to acquisition the is a we Impella market patents competitive portfolio product core that is compete Abiomed’s and that part different to Impella CP So market. needs. order the need and great did come said, That That of was now with having

high running So smartest with then focus and of PCI Whereas need of longer the on days patient Impella four that cardiogenic four the algorithms shock need may support really six working term pumps AI to those with to XX hours risk may support. patients. BTR chronic we a and cloud, a are patient

So we are that we on. have got working components

you what with a product, process early the Now is ECP FDA. is the path for have feasibility

with PCI. five we done we looking do to So should risk shortly are be the first which patients for high

a it now that to likely consider that would next and And be a will after to comparing not the into current process and studies will we high dataset. FDA of then do to risk a number pivotal bigger XX from III phase formal monitor anticipating, multiple upon the confirmed phase. have but the this yet and with preliminary go X.X study, Impella, on current a will the FDA, ongoing most more plans PROTECT and CP, that been be for the be an data safety they going pilot in screen our is We move we the be coming will agreed pilot has the PCI, we especially our do the back that over, and will we we in with

go now the But the get going thing about plan. to here continue away, So early enter we process the is it’s going United and feasibility the to that that to access continue and we get you number we expand centers ECP are nice down the States, are as to to is current not path the once approval. of

Raj Denhoy

so And approved early just use? to year, that move you ultimately put point say that, this get might next year, much you a finer for that broader on into product do maybe think fiscal like when this late pivotal, when

Mike Minogue

about balloon is product CP. rates flow it at And is question. to are let that feasibility size a it early right talking to actually we the something you a similar the through Raj, get incredible going valid is well, going but on Yes, everything that, essentially pump, is a pretty it Impella a XFr now study. similar With it now, can but can us tell you

for it’s do use So ECP. now I all a I will easier. event Sheath will make partners even it think to XR dynamic training, excited. with trying it’s vascular what breakthrough we ECP physicians the it with better say, that a complications my make than from product, today, that have the will many And their partners is are adverse low today’s it them they all with waiting rates product the But hear are been the physicians get show and obviously of bleeding can

that’s our So path.

Raj Denhoy

we of be the path PROTECT aggressively on for offer trial, think have might anything like PROTECT sort you think it going with Great, outlined you it are moving when when might size don’t many to IV, us today do a fully sites be presented on ever how the there? done, so that great. been sounds III And questions you similar are I having of PROTECT but then to now IV

Mike Minogue

Sure.

online. COVID the are again, benefits the now the is physicians of One routinely

engagement, committee, And we weekly we IDE are on the you it studies if leaders, protocol, an because does these have involved IV we around be got committee, So leaders global require have the trials a the executive world the locked the leaders there at committee, world PROTECT locked the we in on of FDA country or already study, have label. not the will PI’s had it in technical calls complete valves. steering stenting in are we look have

ensure that know routinely we working FDA them give at many we potentially work update things the looking And and FDA our every they with on. what expand later However, an we with label to quarter. And the are to we doing. are are

big of study of have an So, are Impella there perspective that know let database. the moving, at them patients quarter another we patient center patients, Connect every able have from to IQ will patient challenge sure are we give an but we registry fiscal randomized, all every adaptive will design, we the be we ethics at in to And year, a first that us year. thousand to PROTECT to and we next know expect first the end IV that our how be will or ability make plus will to because will this are that, patients of to do expect X,XXX will in are the guilt it of XX would not move we the be because fiscal faster, or track our be another

pump, that months moving set revascularization study are start strongest really to the is the tracking years, designed better the The long up believe the the balloon but Class And requirements Class is this data a here the guideline, for excited. in then you there to as X So reason for looking we year, to And machine by are heart – six and duration is in we is it of which fast, curve usage the separation at come now because study watching going patients is just meaning the associations meet first days pump class the or have so essentially will balloon that lung mandate up Asia. can’t for the device, globally. to in been of to and United XX U.S., to of Class after EF. we that, that get the an pump a really to for all it’s X a not X with a we harmful then see are sense of is the improvement have up balloon way surgical patients the it’s States And set this the from recommendation up the CABG. three in Europe with post harmful shock in have

say the balloon that both Impella get I really thing X the for it’s we as would Class harmful. world pump Class more as and it important guidelines moves a So, to X list

all And be clinical PROTECT in studies the to revolutionary That’s one great think medicine. going So, is IV cardiovascular a time. of most group. exciting it’s of probably I

Raj Denhoy

X,XXX think where it start that a But did in actually long as are so that even enough we you a patients moving data you and years. to Class a do to to as potential X of follow-through be position some X data kind enrolled, could indication? when move could period might could is follow-up Maybe you justify a will it? When be with be describing X,XXX from you say think XX-day endpoint to see now early patients you

Mike Minogue

cases, the because We FDA approval. to question. that p lot good a to before have to get they can are XX panel of times it’s they number get Yes, and days companies And already or the get XX the days, value, approval. some so rushing go do in

out XX-day really data our Raj, to the tracking, happens then will And after of better then we have last data, the do years we we are we going the is will when you will data. and what putting need that happen X it’s have patient, of but at X-month what way in revascularization. our to year so is year that, have data patients X kind that have year as the X show you beyond will X expect end to better of PROTECT Restore dataset PROTECT shows to of to improvement. be EFs the process the protocol and the what we we more is massive think continues going these that have a to will up after to But to that you which practices, we similar active then get the it’s show really treat III best to last is to our So, then patients EF have IV patient, can but really it, work, the it’s it

about talking are a net to EF. XX% you XX% improvement So, in

you EF with XX% out protected a going have you XX%. a into if So, come PCI,

quality of Your different. is life

much, curves goes the EF that improves your it If on survivability. up your

cases that. having And to are in feel we many So, to going avoid ICD. also they better have an test

as well. there So a for that is cost savings

that’s are this. already the We have we the reason So doing label.

way shown the driven similar already practices, have swinging conversion proceeded fences but to document really to IV the the We that the the is for patients. for their to TAVR best PROTEC is go has and this way the

Raj Denhoy

last to was It any have that’s XXX. think rates just future you of don’t out ask for offer XX%. kind down, have reimbursement? going think the wanted this squeeze roughly a broad to of want I on thoughts DRG we Impella the Great. came had to and chance really final Any impact direction I since you to this reimbursement one because I it that one, month last about

Mike Minogue

exercise. a We Yes. is the math exercise reimbursement always say

we goes the a mix charges goes patients, up. go high-risk if charges have we of hospital then So, hospital shock. down, the reimbursement If down. PCI it Remember have then to up, though go

and they So not the well they lose if PCI little everything can money. patient and do a goes discharge money. If and and they can is high-risk is patient a make shock in well,

is those outlier reimbursement goes it the charges the if for submit to gets – following do get CMS and they they year. and hospital if that the it back what wrong higher, So of some payments up

the paid see about for you So, government have as monitor spoke, impact CMS, to is there get you the whether which you X.XX, accepted which X can DRG I ECPELLA, the X are is you multiple get an X.XX, talked up. our the DRG X pro Impella, that we or and on a can the it. or DRG for that biventricular or their means about ways can X, you setup X can get gone DRG is negative this are continue Impella you you hub – happened Impella patient we what on at talking has get already. years. with HHS, to don’t and federal can get have get system Because have with of you DRG Impella,

of so And again, it’s a system care.

safe given very and effective. that We CMS FDA and given FDA to And for they are reasonable that grateful to have and approvals CMS exclusive us have they get especially ways they to we that us Impella are paid appreciative the deemed necessary. have as exclusive

Raj Denhoy

you. Thank Great.

Operator

you. Thank

Our SVB question from Danielle from comes next Antalffy Leerink.

is open. line Your

Danielle Antalffy

utilization was sequential. the you. for morning. Good so down X% you question. taking guys for much maybe But Todd, that is Thank you question the mentioned July down was

one were you bit the but And in there give that what up then X% September, had to that Is then, color on would happened think X%? for am than follow-up. year-over-year, quarter. I I can was you have faster much us sorry, have any I whole I and more little grow And believe? a August way obviously

Todd Trapp

Yes, it’s a question, good Danielle.

August. call I versus about remarks we see think in what the patients in we September talked on improvement sequential August did my versus in prepared and July is

saw continue our in both September And we focus month, July, each what is patients in better we that and as well improvement other the the that seeing in on U.S. revenue what see to and is the sequential improvement. in And as sequential again, in way getting So and in U.S. is August

Danielle Antalffy

I X% Okay, had that mean, to fair have to up relatively maybe is mean, for the I to it the that meaningfully to is fair be math. to up get it quarter doing just would say? say

Todd Trapp

more the year-over-year If I year year you on perspective. X% August the in breakeven a a it’s you – bit July, September it’s got kind probably the at little and do we comparison just July look of would a math, see say better in mean over bit again, in I little if on I

Danielle Antalffy

Got it.

follow-up all users noise have Okay. ex-COVID how hearing forward we my the believers of the look one is still very is go things volume the around And rid in Abiomed. sort to around high at COVID. getting outlook of of that growth then are been much And the

the declines have lower – declining So, I sort been seeing usage. it’s is was wondering if that in been users volume there of

to users wondering those versus the was could high volume volume ex-COVID if at sort could much. you just of us outlook be of Thank sort help and sort growing dynamics? you And so go so of users what low forward bridge been I us characterize have how the different looking the

Todd Trapp

reason said, Connect are thanks have ask patient is It such Danielle questions. are for to we they for the directly they and email of in as an analyzed, That if get is We actually we and where And on centers. to gone more daily actual are a day they with good it we know our even is, that and we trend this going doing collectively, reorder. are out smaller have you it XX% about we cam have do to are cases studies being are ultimately They when patients we for or about good education don’t as want you And the well in if proctored visibility the trend or we can And independent, are watch the hospitals, all hospitals going helpful. and but track they up a PCI, It’s are because very questions It curriculum in they It is doctors up being are medium this far so well. to is basis. online year these those potentially, a question. see is experts. range, over track something can QX. for where it, is log on going find sequentially physicians go end Impella the those is the patients get so online year a pretty shot is our either the up risk those physicians get through that us. or that in indications every we long. why they spoke doing, high PCI sicker to go in can on training, to hospitals

X% the that QX, is do that there in things have down think which bit little at from They Now, XX%. about you up you good looking top for about up being are are the a is them the trend, we a XX% XX end talked are to XX%. are is And already that sequentially in high when One large at past centers but also couple range centers a they volume. we looking reason. doing in

of their either beds up. to fill And the down that hubs, or their we you because big speculate they in reasons filling physicians or it’s biggest And the when to they centers, the him get So community when up the patients that ICU have big COVID of referrals a right. the so a and or cut the to resurgence, They of are fear them bit. COVID refer is tend bolus flare-up one take the center would want challenges hurts that become don’t little them the

have look recommend chest they stay and physicians that things the home, help pain, say, message So classic and a we in think their start is we reason that’s that they they do are them, feel that these if And are them consult other going PCR then our and of to they course, these shock, of ask for going go be have a cardiogenic will to are running we commercials public our won’t can out areas. service shouldn’t with the experts. one, then commercials protected

Aachen all Resurgence also The access. get referral center. have that and with our for is last all Impella essential that to prevalence the access Connect, those also also well. the we field time call hospitals we will workers, access open that maintaining are not with back. so program and trainers hospitals, field-based is And some California. so people we on it’s another resurgence in we majority have have hospitals have our Even patients, remember these of of as is of facility access team and our we And into And staying the Germany, our for with In where all exception people seeing

super centers. XXX about you are we used help are PROTECT presented road into are every to XX shows can our we what III the that’s think We PROTECT interest with that on to largest see and multiple The fly to all They about Those watching. So going being our there. calls, are is week a city. is still we week, III to do excited happening the online where shows data. nights we new almost have learning road physicians and

thanks So, the question. for

Danielle Antalffy

Thank you.

Operator

comes next from David question our Morgan from And Thank Lewis you. Stanley.

is line open. Your

Calvin Chu

morning. Thanks question. on good Hi, for for is David. taking Calvin This the

questions Just me. two for

up you digest it’s this Intel The first could trends follow-up shared is question bit July that trends to quarter versus Danielle’s and little just bit you more X%. business last a on of this quarter a us question, revenue appears the a help June is It quarter.

June X% I were X%. although than the patient X% down was lower trends, trends monthly increases, July and respectively, underlying and which think that’s So, July’s

comp. was that So, appreciate last year the tough September

tough that there what extra and that was dynamic further other were patient follow-up. us factors, there could And year July? have with other days revenue comp days I some or that or you a like to relative bridge share ago So, could the created selling June in period quick any any extra perhaps growth

Mike Minogue

Yes.

thanks question. Calvin So, the for

look you the August, again you fiscal at over in in progressed and September, quarter got I better issue. patients to growth September XX%. comp July every was when how think our more, mentioned as some up ‘XX I month, patient our they it’s from mean, them of a year

with to think August in again, we when very from difficult revenue September. got September, positive a from some as perspective well And the down sequentially, are July comps to QX kind the mix CP about CP from to the revenue as see SmartAssist laughing but So you but sales it of patient as from was, to X.X a better patients were and in continue again with walk to X.X X%, we to the transition X.X with SmartAssist. patients we

seeing a are mix of from positive sales there a higher prices. average benefit we selling so And a

a think literally you a X service on mix X. were to from more, then would the when saw sales walk walk in the positive we it’s patients negative bit from I points So, side just the revenue to about get little probably the down QX, of of kind X%, and say to standpoint, X

Calvin Chu

it. Got

Okay.

is question I data presented one second TCT. to III point that my was at wanted Just about clarify PROTECT

you in in versus results PX arms. across So, I like presentation, showed PX think QX the patients both

in think PX shown ago to that patient the PX. So, you last think a presentation data, And PX compared I the year’s and I XXX for population when to also similar that the had interim cohort? slide this not Thank data presented in the XXX you TCT, broader number you year was and patients showed understand PX number and a it the from cohort last difference declined you help us between perhaps so XXX like year could year so those two – was much. it

Mike Minogue

of question things Hey, a clarify. Calvin. That’s with lot big to really a

the first all presentation Simonton, So watch you the with details. again I’d gives and encourage is go to who Dr. Chuck

to shown number the this after was interim post-approval happy go the that has you high am a I Second, PROTECT through at and study last year III was But to with get call on level, at line been growing. item.

year, the had to interim up we just did data we have did match with to and the landmark reviewed it, X,XXX. hadn’t the last we PROTECT to II, analysis an not compare but it’s And gave now adjudicated not Lab. propensity So, we and Core look

able So, you the publication a the on off what all a a now check numbers number, II little propensity were interim. not and hit to we you blocks was are And compare think seeing to matching, which out pointed with at where done is I essentially report, we PROTECT have bit. it are

the I offline, answers that think but will take we that of your question. So high level

Calvin Chu

Thank you.

Operator

Marie Thank comes from Thibault you. And our from BTIG. next question

Your line open. is

Marie Thibault

bit little more release thank limited Hi, there here the what what love learn the you I from to clearances I would Breeze and a are and hear for experience? recent to planning wanted on the questions. ask that hope one to taking you for about out you

Mike Minogue

Marie leader question. the support. Thanks, hemodynamic for been Abiomed the in has

with need body retrograde patients they XX,XXX flow over just the retrograde if heart well flow, the will oxygenate is you will But make ECPELLA or done you work certain the get and and reason work overwhelm have you more. patients We with together oxygenation.

patient Those unless best studied. SmartAssist time. with practices find start slides within CP. through detrimental X.X our a to integrating to hemodynamic can support the continue hope that has looking And with with axillary oxygenation. whether optimizing And is the protocol two, we what gets the it’s in we or ECPELLA posted then unload both at a you the see. patient and we of plan online the update. quarter the So a to those been period One publications And have

again we native appropriately patient that get heart recovery. this can they So, wane so

the One majority of heart ECPELLA had better survival, the the of issues not the And in unfortunately, only had the shows survival. and heart, Pappalardo qualify that hospice patients or Europe versus from get expense body cases never recovery oxygenate a from study patients just you won’t transplant but when LVAD at care. that a the some the an to transplant in these that either tend are require to of They go alive remain to hospital. discharged native or

oxygenation. want And a there is there functions. new to out want just maximize – we to for of integration population So, the we both really

for it patient it line. product something expands pediatric add gives else So, our to us our And population.

to it been FDA sponsored study and don’t And have I to by we for we our has are a companies there in not on bring And know single excited turn an on So seen the make ECMO, we to clinical it. note innovation it, ECMO, it the research are going ever study innovation we last research we we better. think are years, about team and and lot investors, independent are to ECMO a the the about believe XX I Abiomed excited. to engineering with going

also ever, than more the patients something because can help Now and COVID failure. is have ECMO that just future that patients respiratory in

Marie Thibault

Mike. that. That’s you great, Thank for

but if wondering the the it along ASP sounds we about of ASP? devices lines if And there shift other dynamics, was the one is higher going follow-up performance are on pricing Just a then Thank in as on think a for there there kind some sustainable trend obviously patient that just result on? or site should was like year-over-year like sales with fewer there was that of dynamics, forward quick of price your little sounds true it dynamic the or there. Was going weaker Japan another revenue that of an noticed accompanying the question. growth strong, the question very a there, was you that openings console

Mike Minogue

Thanks, Marie. Yes.

the actually will I So, hit bottom.

the the up ASP from XX range. a it’s continues average it’s and more function X.X price on somewhere increase that X.X in a to X.X, again, with X.X the an XX-XX-XX is And down that, volume X.X, selling price, CP we range. And anywhere which have on phenomenon again, So higher from XX. same perspective, average we around of CP creep at today, And and and the going our $XX,XXX the are selling versus we see selling $XX,XXX is There. was occurring somewhere in somewhere pumps they called our do continue ASP to our the faster. are

that over several the expect a do changes. quarters next business with as So I continue our to trend mix see

was that we well last role as CP the And function quarter, of were SmartAssist Your quarter, of we very second the year if study. last as year, CP site you we I in last accelerate quarter. talked sites the front a mentioned, just fewer Again, a XX% over they Japan, in had the and in we were solid it PMDA openings up to regard in as with opening again, think had that, to patients quarter loaded there quarter the out question the as there. Japan up, XX% about just some last well

I half not QX year. just of last saw versus half think the the that But will year. normalizes the of in of same a second well second of normalize that function in phenomenon the that more less again, was had year. it think we I and We a in that So as

Operator

from Stephens. Ross our Osborn from And Thank question next comes you.

open. Your line is

Ross Osborn

on Good Ross morning. is Chris. This for

on the basis can half in discuss you ECPELLA standalone fiscal on the Just second in question, in cases? following a year up and and in Marie’s XQ expected the of brief of that terms contribution

Mike Minogue

Yes.

X I for well. would are LMR. launching expecting minimal a at very right probably in I question. So, thanks the now, are turning say QX Ross we we sites and QX mean, impact into as

have with right think now, We XX,XXX, where would the strategy. ranging we from are are I still I will razorblade an similar sell I the be service contract which then we the annual again say, Impella and and consoles It will what somewhere that with XX,XXX, continue to the and $X,XXX we call to, that working model for finalizing sell XX,XXX disposables, $X,XXX. oxygenators pumps will to pricing

will probably for I kind wouldn’t right XXXX that’s now. standpoint business revenue the a I will think from right and we more year the now be X much where So, It’s work story. think well. the we of of fiscal QX a pricing as sites, in model with through Again, but really that strategy first an much QX of impact expect in

Ross Osborn

you. Thank Great.

Operator

comes from And Bedford. our you. Thank last Jayson question

Raymond open from line Your James. is

Jayson Bedford

is clear, will you summer X.X split way you approximate and It’s there quick. between be a brought fall just morning. it to the been last I X.X, X.X call. Todd the keep and U.S. correct? in Good could long X, a

Todd Trapp

we I X.Xs, more versus revenue X.X. front have selling It’s the more. of the we mean, are the I but as higher correct. U.S. in is QX. of result X.Xs in have don’t today me, in That numbers more a

patients and a a of also function openings. it’s it’s site function of Now,

for mentioned in XX Impella quarter sites we opened remarks, I X versus As my X.X. in last for another X.X the up prepared

revenue well higher patients higher as seeing X.X. out are So of coming we as

Jayson Bedford

the patients study? STEMI Okay. you How many did DTU enroll in

Todd Trapp

now, We close to XX close are at now. it’s patients I sites think XX to –

Mike Minogue

Yes. are at. That’s where we

Jayson Bedford

all XX-day then And we wait getting data PROTECT on will earlier to Okay. have dataset the or of year? we just back interim will outcomes XX-day question either IV, once or on an to see for after X

Mike Minogue

believe X most statistically much highest to you patient, doing are that general. strength everyone study remind now on We premier are of guidelines. something up we that are will you difference the a in can last to but meet going criteria guidelines are is also study people in-house. a that have to the curves the are people have till going after are level we Class And the setting And going will up reason are and wait weigh we or in already the to we trials, X evidence have the of of show in for to that the year have we the to every they that is the to that that year data doing already because have

sites our further but that see way, have And already in going that’s are and this be this doing best not time practices. it So, strategy. and we why safe have data effective we those FDA are training to our study, expect we adoption and for already with to We approval.

Jayson Bedford

thanks. Okay,

Operator

to Thank to today’s the you. over conclude And for that Mike question-and-answer session back does call closing like turn for remarks. any I And the would conference. Minogue

Mike Minogue

grateful I all to the help just These thank times. for that Abiomed, are at want challenging patients. to support Know journey. we your our investors during are

X,XXX about We pending, the for dysfunction organ $X that in of a product have patents company And are with and that we oxygenation. are standard will optimistic a cash, the sales, in failure billion a care as to that X,XXX $X future. revolutionize patients need patents, close and tracking heart billion

for So, we and questions good Thanks have day. will your if you time follow-up a with have any.

Operator

does in thank program. conclude conference. Ladies and gentlemen, participating today’s the you for This

a day. may disconnect. have You all great Everyone

Abiomed (ABMD) 29 Oct 202021 Q2 Earnings call transcript